135 related articles for article (PubMed ID: 27977052)
1. Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.
Prebet T; Delaunay J; Wattel E; Braun T; Cony-Makhoul P; Dimicoli S; Wickenhauser S; Lejeune J; Chevret S; Chermat F; Fenaux P; Vey N;
Br J Haematol; 2018 Mar; 180(5):735-737. PubMed ID: 27977052
[No Abstract] [Full Text] [Related]
2. Eprenetapopt Plus Azacitidine in
Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).
Ades L; Guerci-Bresler A; Cony-Makhoul P; Legros L; Sebert M; Braun T; Delaunay J; Desseaux K; Chevret S; Fenaux P
Haematologica; 2019 Apr; 104(4):e131-e133. PubMed ID: 30381302
[No Abstract] [Full Text] [Related]
4. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Prebet T; Braun T; Beyne-Rauzy O; Dreyfus F; Stammatoullas A; Wattel E; Ame S; Raffoux E; Delaunay J; Charbonnier A; Adès L; Fenaux P; Vey N
Leuk Res; 2014 Jan; 38(1):29-33. PubMed ID: 23953882
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Sekeres MA; Othus M; List AF; Odenike O; Stone RM; Gore SD; Litzow MR; Buckstein R; Fang M; Roulston D; Bloomfield CD; Moseley A; Nazha A; Zhang Y; Velasco MR; Gaur R; Atallah E; Attar EC; Cook EK; Cull AH; Rauh MJ; Appelbaum FR; Erba HP
J Clin Oncol; 2017 Aug; 35(24):2745-2753. PubMed ID: 28486043
[TBL] [Abstract][Full Text] [Related]
6. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
7. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the
Ades L; Prebet T; Stamatoullas A; Recher C; Guieze R; Raffoux E; Bouabdallah K; Hunault M; Wattel E; Stalnikiewicz L; Toma A; Dombret H; Vey N; Sebert M; Gardin C; Chaffaut C; Chevret S; Fenaux P
Haematologica; 2017 Apr; 102(4):728-735. PubMed ID: 28034993
[TBL] [Abstract][Full Text] [Related]
9. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Garcia-Manero G; Montalban-Bravo G; Berdeja JG; Abaza Y; Jabbour E; Essell J; Lyons RM; Ravandi F; Maris M; Heller B; DeZern AE; Babu S; Wright D; Anz B; Boccia R; Komrokji RS; Kuriakose P; Reeves J; Sekeres MA; Kantarjian HM; Ghalie R; Roboz GJ
Cancer; 2017 May; 123(6):994-1002. PubMed ID: 28094841
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
11. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
Itzykson R; Thépot S; Beyne-Rauzy O; Ame S; Isnard F; Dreyfus F; Salanoubat C; Taksin AL; Chelgoum Y; Berthon C; Malfuson JV; Legros L; Vey N; Turlure P; Gardin C; Boehrer S; Ades L; Fenaux P;
Leuk Res; 2012 Apr; 36(4):397-400. PubMed ID: 22177456
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG
Leukemia; 2017 Dec; 31(12):2799-2806. PubMed ID: 28546581
[TBL] [Abstract][Full Text] [Related]
13. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Thépot S; Ben Abdelali R; Chevret S; Renneville A; Beyne-Rauzy O; Prébet T; Park S; Stamatoullas A; Guerci-Bresler A; Cheze S; Tertian G; Choufi B; Legros L; Bastié JN; Delaunay J; Chaury MP; Sanhes L; Wattel E; Dreyfus F; Vey N; Chermat F; Preudhomme C; Fenaux P; Gardin C;
Haematologica; 2016 Aug; 101(8):918-25. PubMed ID: 27229713
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
Montalban-Bravo G; Huang X; Naqvi K; Jabbour E; Borthakur G; DiNardo CD; Pemmaraju N; Cortes J; Verstovsek S; Kadia T; Daver N; Wierda W; Alvarado Y; Konopleva M; Ravandi F; Estrov Z; Jain N; Alfonso A; Brandt M; Sneed T; Chen HC; Yang H; Bueso-Ramos C; Pierce S; Estey E; Bohannan Z; Kantarjian HM; Garcia-Manero G
Leukemia; 2017 Feb; 31(2):318-324. PubMed ID: 27795561
[TBL] [Abstract][Full Text] [Related]
16. Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.
Yee KW; Brandwein J; Schimmer AD; Gupta V; Del Bel R; Xu W; Minden MD; Schuh AC
Br J Haematol; 2014 Jul; 166(2):303-6. PubMed ID: 24650042
[No Abstract] [Full Text] [Related]
17. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Scherman E; Malak S; Perot C; Gorin NC; Rubio MT; Isnard F
Leukemia; 2012 Apr; 26(4):822-4. PubMed ID: 21997572
[No Abstract] [Full Text] [Related]
18. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Bally C; Thépot S; Quesnel B; Vey N; Dreyfus F; Fadlallah J; Turlure P; de Botton S; Dartigeas C; de Renzis B; Itzykson R; Fenaux P; Adès L
Leuk Res; 2013 Jun; 37(6):637-40. PubMed ID: 23499498
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
20. The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Nishiyama-Fujita Y; Nakazato T; Kamiya T; Mizuno K; Ito C; Ogura S; Sakurai A; Tanigawa T; Akimoto M; Aisa Y
Hematol Oncol; 2020 Oct; 38(4):611-613. PubMed ID: 32515069
[No Abstract] [Full Text] [Related]
[Next] [New Search]
